Next Article in Journal
Circulatory and Urinary B-Vitamin Responses to Multivitamin Supplement Ingestion Differ between Older and Younger Adults
Previous Article in Journal
Dietary Intervention Modulates the Expression of Splicing Machinery in Cardiovascular Patients at High Risk of Type 2 Diabetes Development: From the CORDIOPREV Study
Open AccessArticle

PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes

1
Department of Medicine, University of Auckland, Auckland 1142, New Zealand
2
Discipline of Nutrition & Dietetics, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand
3
Department of Surgery, University of Auckland, Auckland 1142, New Zealand
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(11), 3530; https://doi.org/10.3390/nu12113530
Received: 13 October 2020 / Revised: 9 November 2020 / Accepted: 16 November 2020 / Published: 17 November 2020
Both intermittent fasting and specific probiotics have shown promise in improving glucose tolerance with a potential for synergistic effects through alterations to gut microbiota. In this randomized, double-blinded, two-arm feasibility study, we investigated whether intermittent fasting, supplemented with Lacticaseibacillus rhamnosus HN001 probiotic, reduces HbA1c in individuals with prediabetes. All participants with HbA1c 40–50 mmol/mol commenced intermittent fasting (2 days per week of calorie restriction to 600–650 kcal/day) and were randomized 1:1 to either daily probiotic (Lacticaseibacillus rhamnosus HN001) or placebo for 12 weeks. The primary outcome was a change in HbA1c. Secondary outcomes included changes in anthropometry, body composition, glucoregulatory markers, lipids, hunger hormones, liver enzymes, inflammatory markers, gut hormones, calorie and macronutrient intake, quality of life, hunger, mood and eating behavior. Of 33 participants who commenced the trial, 26 participants (mean age 52 years, body mass index (BMI) 34.7 kg/m2) completed the intervention (n = 11 placebo, n = 15 probiotic). HbA1c decreased from 43 ± 2.7 mmol/mol to 41 ± 2.3 mmol/mol, p < 0.001, with average of 5% weight loss. No significant between-group differences were seen in primary or secondary outcomes except for social functioning (p = 0.050) and mental health (p = 0.007) scores as improvements were seen in the probiotic group, but not in the placebo group. This study shows additional psychological benefits of probiotic supplementation during intermittent fasting to achieve weight loss and glycemic improvement in prediabetes. View Full-Text
Keywords: intermittent fasting; probiotics; Lacticaseibacillus rhamnosus HN001; prediabetes intermittent fasting; probiotics; Lacticaseibacillus rhamnosus HN001; prediabetes
Show Figures

Figure 1

MDPI and ACS Style

Tay, A.; Pringle, H.; Penning, E.; Plank, L.D.; Murphy, R. PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes. Nutrients 2020, 12, 3530.

AMA Style

Tay A, Pringle H, Penning E, Plank LD, Murphy R. PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes. Nutrients. 2020; 12(11):3530.

Chicago/Turabian Style

Tay, Audrey; Pringle, Hannah; Penning, Elise; Plank, Lindsay D.; Murphy, Rinki. 2020. "PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes" Nutrients 12, no. 11: 3530.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop